Identification | More | [Name]
L-Cyclohexylalanine | [CAS]
27527-05-5 | [Synonyms]
2-AMINO-3-CYCLOHEXYLPROPANOIC ACID 3-CYCLOHEXYL-L-ALANINE 3-CYCLOHEXYL-L-ALANINE HYDROCHLORIDE 3-CYCLOHEXYL-L-ALANINE HYDROCHLORIDE SALT BETA-CYCLOHEXYL-ALANINE HCL BETA-CYCLOHEXYL-L-ALANINE BETA-CYCLOHEXYL-L-ALANINE HYDROCHLORIDE H-BETA-CYCLOHEXYL-ALA-OH HCL H-CHA-OH H-CHA-OH HCL HEXAHYDRO-L-PHENYLALANINE HCL HEXAHYDRO-L-PHENYLALANINE HYDROCHLORIDE H-L-CHA-OH H-PHE(HEXAHYDRO)-OH HCL L-2-AMINO-3-CYCLOHEXYL-PROPIONIC ACID L-2-AMINO-3-CYCLOHEXYL-PROPIONIC ACID HYDROCHLORIDE L-2-AMINO-3-HEXAHYDROPHENYL-PROPIONIC ACID HYDROCHLORIDE L-3-CYCLOHEXYL-ALANINE L-3-CYCLOHEXYLALANINE HYDROCHLORIDE SALT L-CHA | [EINECS(EC#)]
1308068-626-2 | [Molecular Formula]
C9H17NO2 | [MDL Number]
MFCD00190861 | [Molecular Weight]
171.24 | [MOL File]
27527-05-5.mol |
Safety Data | Back Directory | [Hazard Codes ]
Xi | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S22:Do not breathe dust . S24/25:Avoid contact with skin and eyes . S37/39:Wear suitable gloves and eye/face protection . S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . | [WGK Germany ]
3
| [F ]
10 | [Hazard Note ]
Irritant |
Questions And Answer | Back Directory | [Description]
L-Cyclohexylalanine is a kind of amino acid analog. It has some pharmacological effects. Study has shown that some of its derivatives exhibit potent bactericidal activity against drug-resistant gram-positive pathogens. Its derivatives can also act as dipeptidyl peptidase-IV inhibitor, which can be used for the treatment or prevention of diabetes.
| [References]
http://nizetlab.ucsd.edu/Publications/CombinatorialLibrary.pdf
Duffy, Joseph L, et al. "Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes." CN, CN 1960990 A. 2007.
Aarstad, K, T. L. Zimmer, and S. G. Laland. "The fidelity of gramicidin S synthetase." European Journal of Biochemistry 112.2(1980):335-338.
|
|
|